BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

911 related articles for article (PubMed ID: 34503576)

  • 1. Synaptic tau: A pathological or physiological phenomenon?
    Robbins M; Clayton E; Kaminski Schierle GS
    Acta Neuropathol Commun; 2021 Sep; 9(1):149. PubMed ID: 34503576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A NH2 tau fragment targets neuronal mitochondria at AD synapses: possible implications for neurodegeneration.
    Amadoro G; Corsetti V; Stringaro A; Colone M; D'Aguanno S; Meli G; Ciotti M; Sancesario G; Cattaneo A; Bussani R; Mercanti D; Calissano P
    J Alzheimers Dis; 2010; 21(2):445-70. PubMed ID: 20571215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synaptic Mitochondria: An Early Target of Amyloid-β and Tau in Alzheimer's Disease.
    Torres AK; Jara C; Park-Kang HS; Polanco CM; Tapia D; Alarcón F; de la Peña A; Llanquinao J; Vargas-Mardones G; Indo JA; Inestrosa NC; Tapia-Rojas C
    J Alzheimers Dis; 2021; 84(4):1391-1414. PubMed ID: 34719499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurodegeneration and plasticity.
    Arendt T
    Int J Dev Neurosci; 2004 Nov; 22(7):507-14. PubMed ID: 15465280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dissecting phenotypic traits linked to human resilience to Alzheimer's pathology.
    Perez-Nievas BG; Stein TD; Tai HC; Dols-Icardo O; Scotton TC; Barroeta-Espar I; Fernandez-Carballo L; de Munain EL; Perez J; Marquie M; Serrano-Pozo A; Frosch MP; Lowe V; Parisi JE; Petersen RC; Ikonomovic MD; López OL; Klunk W; Hyman BT; Gómez-Isla T
    Brain; 2013 Aug; 136(Pt 8):2510-26. PubMed ID: 23824488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monitoring synaptic pathology in Alzheimer's disease through fluid and PET imaging biomarkers: a comprehensive review and future perspectives.
    Lista S; Santos-Lozano A; Emanuele E; Mercuri NB; Gabelle A; López-Ortiz S; Martín-Hernández J; Maisto N; Imbimbo C; Caraci F; Imbimbo BP; Zetterberg H; Nisticò R
    Mol Psychiatry; 2024 Mar; 29(3):847-857. PubMed ID: 38228892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulatable transgenic mouse models of Alzheimer disease: onset, reversibility and spreading of Tau pathology.
    Hochgräfe K; Sydow A; Mandelkow EM
    FEBS J; 2013 Sep; 280(18):4371-81. PubMed ID: 23517246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synaptic Plasticity, Dementia and Alzheimer Disease.
    Skaper SD; Facci L; Zusso M; Giusti P
    CNS Neurol Disord Drug Targets; 2017; 16(3):220-233. PubMed ID: 28088900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of microtubule-associated protein tau phosphorylation in Alzheimer's disease.
    Ma RH; Zhang Y; Hong XY; Zhang JF; Wang JZ; Liu GP
    J Huazhong Univ Sci Technolog Med Sci; 2017 Jun; 37(3):307-312. PubMed ID: 28585125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Significance of tau in the development of Alzheimer's disease].
    Takashima A
    Brain Nerve; 2010 Jul; 62(7):701-8. PubMed ID: 20675874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dendritic Tau in Alzheimer's Disease.
    Ittner A; Ittner LM
    Neuron; 2018 Jul; 99(1):13-27. PubMed ID: 30001506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minimalistic in vitro systems for investigating tau pathology.
    Hallinan GI; Pitera AP; Patel P; West J; Deinhardt K
    J Neurosci Methods; 2019 May; 319():69-76. PubMed ID: 30278185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional Integrity of Synapses in the Central Nervous System of Cognitively Intact Individuals with High Alzheimer's Disease Neuropathology Is Associated with Absence of Synaptic Tau Oligomers.
    Singh A; Allen D; Fracassi A; Tumurbaatar B; Natarajan C; Scaduto P; Woltjer R; Kayed R; Limon A; Krishnan B; Taglialatela G
    J Alzheimers Dis; 2020; 78(4):1661-1678. PubMed ID: 33185603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The intersection of amyloid beta and tau at synapses in Alzheimer's disease.
    Spires-Jones TL; Hyman BT
    Neuron; 2014 May; 82(4):756-71. PubMed ID: 24853936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Axonal transport, tau protein, and neurodegeneration in Alzheimer's disease.
    Terwel D; Dewachter I; Van Leuven F
    Neuromolecular Med; 2002; 2(2):151-65. PubMed ID: 12428809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A{beta} accelerates the spatiotemporal progression of tau pathology and augments tau amyloidosis in an Alzheimer mouse model.
    Hurtado DE; Molina-Porcel L; Iba M; Aboagye AK; Paul SM; Trojanowski JQ; Lee VM
    Am J Pathol; 2010 Oct; 177(4):1977-88. PubMed ID: 20802182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Present and future of the tau dementia therapy].
    Takashima A
    Rinsho Shinkeigaku; 2013; 53(11):1040-2. PubMed ID: 24291873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amyloid-β and tau: the trigger and bullet in Alzheimer disease pathogenesis.
    Bloom GS
    JAMA Neurol; 2014 Apr; 71(4):505-8. PubMed ID: 24493463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clogging of axons by tau, inhibition of axonal traffic and starvation of synapses.
    Mandelkow EM; Stamer K; Vogel R; Thies E; Mandelkow E
    Neurobiol Aging; 2003 Dec; 24(8):1079-85. PubMed ID: 14643379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathological Changes of Tau Related to Alzheimer's Disease.
    Chu D; Liu F
    ACS Chem Neurosci; 2019 Feb; 10(2):931-944. PubMed ID: 30346708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.